<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03857763</url>
  </required_header>
  <id_info>
    <org_study_id>HBAE-01</org_study_id>
    <nct_id>NCT03857763</nct_id>
  </id_info>
  <brief_title>A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University Fourth Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of apatinib plus concurrent
      neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The pathological complete response rate(pCR)</measure>
    <time_frame>within 3 weeks after surgery</time_frame>
    <description>The lesion disappeared completely by pathology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0-resection rate</measure>
    <time_frame>within 3 weeks after surgery</time_frame>
    <description>There was no residual by the microscope</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival(DFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Baseline to measured date of recurrence or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1year</time_frame>
    <description>Baseline to measured date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events Toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>Adverse events Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.The number of Participants with adverse events will be recorded at each treatment visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Apatinib+Paclitaxel+Cisplatin+RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib：250mg,po,qd, d1-35; Paclitaxel：50mg/m2 iv, d1，8，15，22，29; Cisplatin: 30mg/m2 iv, d1，8，15，22，29; Radiotherapy：41.4Gy/23f , 1.8Gy/f，5 f/w</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Apatinib,Paclitaxel,Cisplatin,RT</intervention_name>
    <description>Apatinib Mesylate Tablets 250mg qd p.o. d1-35; Paclitaxel：50mg/m2 iv d1，8，15，22，29; Cisplatin: 30mg/m2 iv d1，8，15，22，29; RT：41.4Gy/23f , 1.8Gy/f，5 f/w</description>
    <arm_group_label>Apatinib+Paclitaxel+Cisplatin+RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age:18 to 70 years old (man or female);

          2. Pathologically diagnosed with esophageal squamous cell carcinoma;

          3. Patients with Stage for Ⅱ-Ⅲ(T2-4N0/+M0) (According to transesophageal ultrasonography;

          4. Patients with measurable lesions(According to the criteria in RECIST1.1);

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;

          6. Life expectancy greater than or equal to 3 months;

          7. Major organ function has to meet the following certeria:

        (1) For results of blood routine test

          1. HB≥80g/L;

          2. ANC≥1.5×109/L;

          3. PLT≥90×109/L; (2) For results of blood biochemical test

        a) ALT and AST≤2.5×ULN; b) TBIL&lt;1.5×ULN; c) Serum creatinine ≤1.5×ULN; 8. Doctors believe
        that treatment can bring benefits to patients; 9. Participants were willing to join in this
        study, and written informed consent, good adherence, cooperate with the follow-up.

        Exclusion Criteria:

          1. Have received prior treatment with chemotherapy or radiotherapy；

          2. Have high blood pressure and antihypertensive drug treatment can not control;

          3. Patients with severe cardiovascular disease ;

          4. Accompanied by esophageal perforation and esophagotracheal fistula;

          5. Patients with active bleeding or bleeding tendency;

          6. Pregnant or lactating women;

          7. The researchers think inappropriate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2019</study_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

